128 results
8-K
EX-99.1
FGEN
FibroGen Inc
18 Dec 18
FibroGen Announces Approval of Roxadustat in China for the Treatment of
12:00am
our decade-long commitment to bringing innovative medicine to people in China. We look forward to bringing roxadustat to patients worldwide.”
Chris … ten years ago, FibroGen made the decision to develop roxadustat, afirst-in-class investigational candidate, in China as a Domestic Class 1 Innovative
8-K
EX-99.1
FGEN
FibroGen Inc
21 Aug 19
Roxadustat Approved In China for Treatment of Anemia In Chronic Kidney Disease Patients Not Receiving Dialysis
4:39pm
in our multi-year commitment to bringing critically-needed and innovative medicines to a growing CKD population in China,” said Ms. Chris Chung, Senior … , a Beijing-based subsidiary of FibroGen, Inc., sponsored the development and registration of roxadustat as a Domestic Class 1 Innovative Drug. FibroGen
8-K
EX-99.1
FGEN
FibroGen Inc
25 Jul 23
FibroGen Announces Leadership Transition
8:32am
readouts, advancing our innovative pipeline, and continuing to build on our success with roxadustat in China and the nearly 30 other countries in which … -inducible factor (HIF) to advance innovative medicines for the treatment of unmet needs. Pamrevlumab, an anti-CTGF human monoclonal antibody
8-K
EX-99.1
FGEN
FibroGen Inc
5 Jun 19
Fibrogen Appoints Suzanne Blaug to Board of Directors
5:15pm
added. “I look forward to working with Tom Neff and the entire Board of Directors in growing value for shareholders and advancing these innovative … growth factor (CTGF) biology, and clinical development to advance innovative medicines
Page 1 of 2
for the treatment of anemia, fibrotic disease
8-K
EX-99.1
FGEN
FibroGen Inc
6 Jan 20
Fibrogen Names Enrique Conterno As Chief Executive Officer
5:23pm
and continue the advancement of our clinical programs.”
“I am energized to join a company with such an innovative pipeline, as well as the first-in-class … expertise in hypoxia-inducible factor (HIF) and connective tissue growth factor (CTGF) biology, and clinical development to advance innovative medicines
8-K
EX-99.1
l9j5fs8yu12fob4xv4d
6 Aug 20
FibroGen Announces New Appointments to its Board of Directors
4:06pm
8-K
EX-99.1
maex4bescgn0e qit
17 Jun 21
FibroGen and HiFiBiO Announce Transformative Partnership to
4:16pm
8-K
EX-99.1
g5bt60jej 2iy568
26 Aug 19
Departure of Directors or Certain Officers
9:04am
8-K
EX-99.1
dc556zk
31 May 18
Astellas and FibroGen Announce Topline Results
8:00am
8-K
EX-99.1
2al rmzlwa
13 Jan 20
Regulation FD Disclosure
9:01am
8-K
EX-99.1
r1yuq rq1
22 Jul 19
Other Events
8:00am
8-K
EX-99.1
ejt02bwqdv3q7hkj0l
1 Oct 18
Other Events
12:00am
8-K
EX-99.1
5fwfi7i3lrwdy65 87
2 Dec 19
FibroGen Announces Roxadustat Inclusion in China’s National Reimbursement Drug List
7:10am
8-K
EX-99.1
h0wem9b0ntz1
30 Jan 20
Astellas Submits Supplemental New Drug Application for Approval of
4:40pm
8-K
EX-99.2
8kk1e n7sc21
24 Jul 19
Other Events
9:46pm
8-K
EX-99.1
iqv6sbs7an1bhul30ux
20 Sep 19
Roxadustat Approved in Japan for the Treatment of Anemia Associated with Chronic Kidney Disease in Dialysis Patients
9:00am
8-K
EX-99.2
2uwbuqnyt0f8d
12 Nov 19
FibroGen Reports Third Quarter 2019 Financial Results
8:16am
8-K
EX-99.1
fbsvi93235hrn
25 Jun 21
Astellas Receives Positive CHMP Opinion for EVRENZOTM (roxadustat) for Adult Patients with Symptomatic Anemia of Chronic Kidney Disease
5:26pm
8-K
EX-99.1
wd6jkb0
12 Nov 19
FibroGen Reports Third Quarter 2019 Financial Results
8:16am
8-K
EX-99.1
apvotp28
30 Oct 18
Other Events
8:01am